ALIM Shares Outstanding History
Below is a table of the ALIM shares outstanding history going back to 4/22/2010:

Date ALIM Shares Outstanding
4/22/20102.03M
6/1/20102.07M
8/10/20102.08M
11/5/20102.08M
5/4/20112.09M
8/3/20112.09M
11/3/20112.10M
12/31/20112.10M
5/9/20122.10M
8/8/20122.10M
11/2/20122.10M
3/26/20132.10M
5/7/20132.10M
8/8/20132.11M
11/8/20132.11M
2/28/20142.53M
5/7/20142.69M
8/7/20142.69M
11/12/20142.95M
3/6/20152.96M
5/8/20152.96M
8/7/20152.96M
11/5/20152.97M
3/11/20163.00M
5/4/20163.01M
8/4/20163.05M
11/3/20164.32M
3/1/20174.32M
5/10/20174.33M
8/8/20174.60M
11/2/20174.61M
2/28/20184.67M
5/7/20184.67M
7/31/20184.67M
11/7/20184.67M
2/22/20194.73M
5/6/20194.73M
8/5/20194.73M
3/13/20181.25M
11/4/20194.96M
11/15/20194.96M
2/27/20204.97M
5/4/20205.03M
8/3/20205.03M
10/29/20205.13M
3/1/20215.75M
5/3/20216.92M

Also see: ALIM Market Cap History
ALIM YTD Return
ALIM Historical Shares Outstanding:
+11.73% CAGR
ALIM Historical Shares Outstanding: +11.73% CAGR

Mouse over chart for data details
4/22/2010 ...5/3/2021
Alimera Sciences is a pharmaceutical company that is engaged in the commercialization and development of prescription ophthalmic pharmaceuticals. Co.'s commercial product is ILUVIEN®, an intravitreal implant that treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. ILUVIEN was initially developed to treat diabetic macular edema, a disease of the retina that affects individuals with diabetes and can lead to vision loss and blindness. Co. commercially markets ILUVIEN in the United States, Germany, the United Kingdom, Portugal and Ireland. Co. has three segments: the United States, International and Other. We show 47 historical shares outstanding datapoints in our coverage of ALIM's shares outstanding history.

Understanding the changing numbers of ALIM shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ALIM versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ALIM by allowing them to research ALIM shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes
Get Free SEC filing alerts for ALIM:
ALIM SEC Filing Email Alerts ServiceExternal link
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Alimera Sciences (ALIM) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

ALKS Shares Outstanding History
ALNA Shares Outstanding History
ALNY Shares Outstanding History
ALOG Shares Outstanding History
ALPN Shares Outstanding History
ALQA Shares Outstanding History
ALRN Shares Outstanding History
ALT Shares Outstanding History
ALXN Shares Outstanding History
AMAG Shares Outstanding History
More Healthcare companies »

 

ALIM Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2021, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.